BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EndoTAG-1: Additional Phase II data

Additional data from an open-label, active-controlled, international Phase II trial in 133 evaluable TNBC patients showed that once-weekly 22 mg/m 2 EndoTAG-1 plus 70 mg/m 2 paclitaxel led to a median OS of 13 months vs. 11.9 months for twice-weekly 44 mg/m 2 EndoTAG-1 monotherapy and 10.1 months for once-weekly 90 mg/m 2 paclitaxel monotherapy. In the per protocol (PP) population (n=124), median OS was 15.1 months for...

Read the full 316 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >